Eosinophilia associated with clozapine therapy | Zendy

Lam Y. W. Francis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Eosinophilia associated with clozapine therapy

Author(s) -

Lam Y. W. Francis

Publication year - 2021

Publication title -

the brown university psychopharmacology update

Language(s) - English

Resource type - Journals

eISSN - 1556-7532

pISSN - 1068-5308

DOI - 10.1002/pu.30740

Subject(s) - leukopenia , clozapine , medicine , eosinophilia , neutropenia , eosinophil , limiting , white blood cell , schizophrenia (object oriented programming) , blood count , gastroenterology , chemotherapy , psychiatry , mechanical engineering , asthma , engineering

Clozapine is used in the management of treatment‐resistant schizophrenia. However, its utility is limited by the occurrence of agranulocytosis, neutropenia, and leukopenia in up to 3% of patients, necessitating regular monitoring of hematological laboratory indices. In addition, several cases of self‐limiting eosinophilia have been reported in the literature, with most cases occurring 4 weeks after treatment initiation and rarely exceeding a 35% relative eosinophil count (percentage of white blood cells that are eosinophils).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research